Takeda Pharmaceutical Co. Ltd.'s ALK inhibitor Alunbrig is now in position to challenge next-generation anaplastic lymphoma kinase (ALK) inhibitors in mutated non-small cell lung cancer (NSCLC) after pummeling Pfizer Inc.'s first-to-market Xalkori in the Phase III ALTA-1 study.
Alunbrig (brigatinib) received accelerated US FDA approval in April 2017 for use in ALK-positive NSLC after development of tolerance to...